![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/07/02/2907813/0/en/Olema-Oncology-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/06/04/2893454/0/en/Olema-Oncology-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/05/28/2888896/0/en/Olema-Oncology-to-Participate-in-Upcoming-Investor-Conferences-in-June.html
https://www.globenewswire.com/news-release/2024/05/15/2882291/0/en/Olema-Oncology-Announces-Promising-New-Data-for-Palazestrant-in-Combination-with-Ribociclib-Presented-at-the-2024-ESMO-Breast-Cancer-Congress.html
https://www.globenewswire.com/news-release/2024/05/08/2878169/0/en/Olema-Oncology-Reports-First-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html
https://www.globenewswire.com/news-release/2024/05/08/2877691/0/en/Olema-Oncology-Announces-New-Clinical-Data-for-Palazestrant-in-Combination-with-Ribociclib-to-be-Presented-at-the-2024-ESMO-Breast-Cancer-Annual-Congress.html
https://www.globenewswire.com/news-release/2024/05/02/2874773/0/en/Olema-Oncology-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/05/01/2873109/0/en/Olema-Oncology-to-Participate-in-Upcoming-Investor-Conferences-in-May.html
https://www.globenewswire.com/news-release/2024/04/08/2859599/0/en/Olema-Oncology-to-Participate-in-Canaccord-Genuity-2024-Horizons-in-Oncology-Virtual-Conference.html
https://www.globenewswire.com/news-release/2024/04/02/2856485/0/en/Olema-Oncology-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html